Sermorelin 503A Status (2026): Can Pharmacies Compound It?
Sermorelin is not an FDA-approved drug today, but it is one of the peptides with the clearest legal path to a prescription. It was approved by the FDA as Geref until the maker discontinued it, and in 2013 the FDA formally determined that the withdrawal was not for reasons of safety or effectiveness. That history is why licensed 503A compounding pharmacies prepare sermorelin from a provider’s prescription. Here is how the 503A rules work, where sermorelin sits on the FDA’s lists as of October 2026, and what that means for you.
Key facts
- Former approval: sermorelin acetate was the active ingredient in Geref (NDA 20-443 and NDA 19-863), made by EMD Serono.
- Withdrawal: the maker discontinued Geref in 2008; the FDA withdrew the approvals effective June 18, 2009.
- Not for safety reasons: on March 4, 2013, the FDA published its determination that Geref was not withdrawn for safety or effectiveness reasons.
- 503A lists: as of the FDA’s May 14, 2026 update, sermorelin is not on the 503A bulks list and not in any of the three 503A nomination categories, including Category 2 (safety concerns).
- 503B: the FDA lists sermorelin acetate in 503B Category 1 and marks it as a component of an FDA-approved drug (list updated March 21, 2025).
Is sermorelin FDA-approved?
Not anymore. The FDA approved Geref in two forms: a diagnostic product and a treatment for growth hormone deficiency in children. In a study of 110 children with growth hormone deficiency, height velocity roughly doubled over six months. EMD Serono stopped making both products in 2008 for business reasons, and the approvals were withdrawn in 2009.
The important part came four years later. When a drug leaves the market, the FDA can be asked whether it left for safety or effectiveness reasons. For Geref, the agency’s answer in the Federal Register was clear: it did not. That finding is what separates sermorelin from peptides that have never been approved for anything, such as BPC-157.
How 503A compounding works
A 503A pharmacy is a traditional compounding pharmacy that prepares medicine for a specific patient based on a prescription. Under section 503A of the Food, Drug, and Cosmetic Act, the raw ingredient (the “bulk drug substance”) must meet one of three conditions:
- It complies with a USP or NF monograph, if one exists.
- It is a component of an FDA-approved drug product, if no monograph exists.
- It appears on the FDA’s 503A bulks list.
Sermorelin has no USP monograph and is not on the bulks list. Compounding pharmacies point to the second condition: sermorelin is the active ingredient of an FDA-approved drug, Geref, whose approval ended for business reasons rather than safety ones. The FDA has not published a sermorelin-specific statement on this reading, so the honest description is that sermorelin is widely and openly compounded on that basis, not that it has been formally cleared for 503A.
Where sermorelin sits on the FDA lists
The FDA keeps two separate sets of lists: one for 503A pharmacies and one for 503B outsourcing facilities.
| List | Sermorelin status | FDA update |
|---|---|---|
| 503A bulks list | Not listed | May 14, 2026 |
| 503A Category 1, 2 or 3 | Not listed in any category | May 14, 2026 |
| 503B Category 1 (under evaluation) | Listed, marked as component of an approved drug | March 21, 2025 |
For 503B, the FDA says it does not intend to take action against outsourcing facilities that compound with Category 1 substances when the conditions of its interim policy are met. For 503A, the more relevant point is what is absent: sermorelin has never been placed in Category 2, the list for substances that raise significant safety concerns. That is the list BPC-157 sat on from 2023 to April 2026, as our BPC-157 legal status explainer describes.
Does the 2026 peptide review change anything for sermorelin?
Not directly. The July 2026 Pharmacy Compounding Advisory Committee meeting reviewed peptides such as BPC-157, TB-500, KPV and MOTS-c for the 503A bulks list. Sermorelin was not on that agenda, because its path does not depend on the bulks list. You can follow every peptide that is under review on our live legal status tracker, and read our PCAC vote breakdown for the full results.
What the evidence shows, and where it is thin
Sermorelin’s approval rested on pediatric growth hormone deficiency. Today it is more often discussed for adults who want to support their natural growth hormone levels, and the evidence for those wellness uses is small and largely uncontrolled. Our sermorelin profile gives it a Peptiblox evidence grade of C for that reason. A regulatory path to a prescription is not the same thing as proof that it works for a given goal.
What it means for you
The good news is that sermorelin has a legitimate, regulated route: a licensed provider evaluates you, writes a prescription if appropriate, and a licensed compounding pharmacy prepares it. Dosing and monitoring are set by that provider, not by a website. Products sold online as “research peptides” are outside that system, whatever the substance’s legal status. If sermorelin is something you want to discuss, bring your questions to a licensed provider, and see our guide on how peptides get prescribed.
Sources
- Federal Register: Determination that GEREF (sermorelin acetate) was not withdrawn for reasons of safety or effectiveness (March 4, 2013)
- FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (updated May 14, 2026)
- FDA: Bulk drug substances nominated for use in compounding under section 503A, three categories (updated May 14, 2026)
- FDA: Bulk drug substances nominated for use in compounding under section 503B, three categories (updated March 21, 2025)
- FDA: Bulk drug substances used in compounding under section 503B of the FD&C Act
- Geref International Study Group. Once daily subcutaneous GHRH therapy accelerates growth in GH-deficient children. J Clin Endocrinol Metab, 1996
Educational content only, not medical advice. Talk to a licensed provider about whether any medicine is right for you.